Akari Therapeutics Plc

1.43+0.0201+1.43%Vol 124.30K1Y Perf -16.57%
Aug 5th, 2022 15:59 DELAYED
BID1.40 ASK1.47
Open1.45 Previous Close1.41
Pre-Market- After-Market-
 - -  - -%
Target Price
5.00 
Analyst Rating
— 0.00
Potential %
249.63 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
60.19 
Earnings Rating
Neutral
Market Cap84.88M 
Earnings Date
28th Sep 2022
Alpha-0.01 Standard Deviation0.23
Beta1.27 

Today's Price Range

1.371.45

52W Range

0.75001.88

5 Year PE Ratio Range

-1.60-1.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
25.45%
1 Month
50.54%
3 Months
26.56%
6 Months
6.72%
1 Year
-16.57%
3 Years
-19.20%
5 Years
-61.86%
10 Years
-

TickerPriceChg.Chg.%
AKTX1.430.02011.43
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
Earnings HistoryEstimateReportedSurprise %
Q03 2021--0.03-
Q02 2021--0.11-
Q01 2021--0.15-
Q04 2020--0.22-
Q03 20200.000.04-
Q02 20200.00-0.28-
Q01 20200.00-0.13-
Q04 20190.00-0.37-
Earnings Per EndEstimateRevision %Trend
12/2020 QR0.00--
12/2020 QR0.00--
12/2021 FY0.00100.00Positive
12/2022 FY-0.01--
Next Report Date28th Sep 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume124.30K
Shares Outstanding59.35K
Shares Float58.03M
Trades Count340
Dollar Volume175.32K
Avg. Volume113.17K
Avg. Weekly Volume170.29K
Avg. Monthly Volume94.59K
Avg. Quarterly Volume74.64K

Akari Therapeutics Plc (NASDAQ: AKTX) stock closed at 1.4301 per share at the end of the most recent trading day (a 1.43% change compared to the prior day closing price) with a volume of 124.30K shares and market capitalization of 84.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Akari Therapeutics Plc CEO is Clive Richardson.

The one-year performance of Akari Therapeutics Plc stock is -16.57%, while year-to-date (YTD) performance is -4.66%. AKTX stock has a five-year performance of -61.86%. Its 52-week range is between 0.75 and 1.88, which gives AKTX stock a 52-week price range ratio of 60.19%

Akari Therapeutics Plc currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 8.81, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -138.05%, a ROC of -233.42% and a ROE of -243.86%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Akari Therapeutics Plc, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akari Therapeutics Plc’s next earnings report date is 28th Sep 2022.

The consensus rating of Wall Street analysts for Akari Therapeutics Plc is (0), with a target price of $5, which is +249.63% compared to the current price. The earnings rating for Akari Therapeutics Plc stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akari Therapeutics Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akari Therapeutics Plc has a Buy technical analysis rating based on Technical Indicators (ADX : 17.37, ATR14 : 0.10, CCI20 : 175.18, Chaikin Money Flow : 0.18, MACD : 0.09, Money Flow Index : 83.55, ROC : 70.27, RSI : 83.18, STOCH (14,3) : 96.94, STOCH RSI : 0.98, UO : 74.41, Williams %R : -3.06), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akari Therapeutics Plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Strong Buy
1.00

Akari Therapeutics Plc

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.

CEO: Clive Richardson

Telephone: +44 2080040270

Address: 75/76 Wimpole Street, London W1G 9RT, , GB

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

71%29%

Bearish Bullish

77%23%

Bearish Bullish

70%30%


News

Stocktwits